Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-human Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adult

NCT02860650 is registered in ClinicalTrials.gov with Janssen Vaccines & Prevention B.V. as lead sponsor.

NCT NCT02860650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02860650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-human Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adult
Lead sponsor
Janssen Vaccines & Prevention B.V.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2016
Completion date
January 31, 2018
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy